分化型甲状腺癌-话题@MedSci

#分化型甲状腺癌#

32篇内容 | 2147人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1322574, encodeId=906313225e475, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=83, createdTime=2017-08-26, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322573, encodeId=09c513225e341, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响, objectType=article, longId=102204, objectId=ee7a1022043f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee7a1022043f, replyNumber=0, likeNumber=84, createdTime=2017-06-18, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee7a1022043f, moduleTitle=J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee7a1022043f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322572, encodeId=3c5713225e271, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Diabetes Technol Ther：挑战指南！并不是所有的高分化型甲状腺癌儿童患者均要接受全甲状腺切除, objectType=article, longId=83324, objectId=4100833249b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4100833249b, replyNumber=0, likeNumber=51, createdTime=2016-12-01, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4100833249b, moduleTitle=Diabetes Technol Ther：挑战指南！并不是所有的高分化型甲状腺癌儿童患者均要接受全甲状腺切除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4100833249b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322571, encodeId=36b413225e1f4, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Thyroid：与分化型甲状腺癌转移相关的突变基因, objectType=article, longId=64900, objectId=7d0764900ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d0764900ce, replyNumber=0, likeNumber=62, createdTime=2016-03-17, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d0764900ce, moduleTitle=Thyroid：与分化型甲状腺癌转移相关的突变基因, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d0764900ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322570, encodeId=61e113225e044, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=滕卫平解读《2014年分化型甲状腺癌和甲状腺结节诊治指南》, objectType=article, longId=58354, objectId=a44a5835443, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44a5835443, replyNumber=0, likeNumber=41, createdTime=2015-11-06, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44a5835443, moduleTitle=滕卫平解读《2014年分化型甲状腺癌和甲状腺结节诊治指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a44a5835443)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322569, encodeId=badb132256966, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=CSE2015：滕卫平教授谈分化型甲状腺癌治疗新近进展, objectType=article, longId=55592, objectId=d8b855592ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b855592ca, replyNumber=0, likeNumber=83, createdTime=2015-09-02, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b855592ca, moduleTitle=CSE2015：滕卫平教授谈分化型甲状腺癌治疗新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b855592ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322568, encodeId=45ed132256840, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=TSH可预测10 mm以上分化型甲状腺癌风险, objectType=article, longId=40249, objectId=49f3402496e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49f3402496e, replyNumber=0, likeNumber=67, createdTime=2014-09-14, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49f3402496e, moduleTitle=TSH可预测10 mm以上分化型甲状腺癌风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49f3402496e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322567, encodeId=c8ff132256eb4, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=CSMO 2014：林岩松谈分化型甲状腺癌手术后放射性碘-131治疗的规范, objectType=article, longId=37668, objectId=e6203e668d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6203e668d4, replyNumber=0, likeNumber=66, createdTime=2014-07-12, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6203e668d4, moduleTitle=CSMO 2014：林岩松谈分化型甲状腺癌手术后放射性碘-131治疗的规范, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6203e668d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322566, encodeId=61f313225664d, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=ASCO 2014：放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究, objectType=article, longId=35952, objectId=9657359522c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9657359522c, replyNumber=0, likeNumber=79, createdTime=2014-06-06, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9657359522c, moduleTitle=ASCO 2014：放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9657359522c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322565, encodeId=b153132256568, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=Lancet Diab & Endo：放射性碘抵抗分化型甲状腺癌的定义和管理, objectType=article, longId=30982, objectId=34463098274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34463098274, replyNumber=0, likeNumber=68, createdTime=2014-02-23, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34463098274, moduleTitle=Lancet Diab & Endo：放射性碘抵抗分化型甲状腺癌的定义和管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34463098274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322564, encodeId=d1431322564ad, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, objectType=article, longId=27071, objectId=93e42e071ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e42e071ee, replyNumber=0, likeNumber=72, createdTime=2013-11-27, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e42e071ee, moduleTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e42e071ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322563, encodeId=7e2613225631c, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=JCEM：二甲双胍可抑制分化型甲状腺癌生长, objectType=article, longId=20016, objectId=202a200167a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=202a200167a, replyNumber=0, likeNumber=64, createdTime=2013-06-11, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=202a200167a, moduleTitle=JCEM：二甲双胍可抑制分化型甲状腺癌生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=202a200167a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322562, encodeId=2ded1322562ea, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=【下载】2012甲状腺结节和分化型甲状腺癌诊治指南, objectType=article, longId=10961, objectId=802110961ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=802110961ee, replyNumber=0, likeNumber=81, createdTime=2012-11-18, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=802110961ee, moduleTitle=【下载】2012甲状腺结节和分化型甲状腺癌诊治指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=802110961ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1322561, encodeId=5830132256168, content=<a href='/topic/show?id=286c31525bd' target=_blank style='color:#2F92EE;'>#分化型甲状腺癌#</a>, objectTitle=2012中国甲状腺结节和分化型甲状腺癌指南, objectType=article, longId=10052, objectId=40d010052fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40d010052fa, replyNumber=0, likeNumber=0, createdTime=2012-10-04, rootId=0, userName=dzx0922889, userId=05a2499, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40d010052fa, moduleTitle=2012中国甲状腺结节和分化型甲状腺癌指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40d010052fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

分化型甲状腺癌

2020-05-29

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

J CLIN ONCOL：III期选择性试验中年龄对lenvatinib治疗放射性碘难治性分化型甲状腺癌疗效和安全性的影响

2017-06-18

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Diabetes Technol Ther：挑战指南！并不是所有的高分化型甲状腺癌儿童患者均要接受全甲状腺切除

2016-12-01

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Thyroid：与分化型甲状腺癌转移相关的突变基因

2016-03-17

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

滕卫平解读《2014年分化型甲状腺癌和甲状腺结节诊治指南》

2015-11-06

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

CSE2015：滕卫平教授谈分化型甲状腺癌治疗新近进展

2015-09-02

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

TSH可预测10 mm以上分化型甲状腺癌风险

2014-09-14

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

CSMO 2014：林岩松谈分化型甲状腺癌手术后放射性碘-131治疗的规范

2014-07-12

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

ASCO 2014：放射性碘治疗无效的晚期分化型甲状腺癌的Ⅲ期研究

2014-06-06

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

Lancet Diab & Endo：放射性碘抵抗分化型甲状腺癌的定义和管理

2014-02-23

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准

2013-11-27

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

JCEM：二甲双胍可抑制分化型甲状腺癌生长

2013-06-11

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

【下载】2012甲状腺结节和分化型甲状腺癌诊治指南

2012-11-18

dzx0922889 (审核中...)

前往app查看评论内容

#分化型甲状腺癌#

2012中国甲状腺结节和分化型甲状腺癌指南

2012-10-04

科室
- - 订阅+
  - 更多科室
工具
服务